Pharmacodynamics of antimicrobial agents and rationale for their dosing

Journal of Chemotherapy

Volumn 9, Issue SUPPL. 1, 1997, Pages 64-73

  Macgowan, A P ^a   Bowker, K E ^a  

^a NONE

Author keywords

Aminoglycosides; Antibiotic dosing; Carbapenems; Cephalosporins; Clinical outcome; Glycopeptides; Penicillins; Pharmacodynamics; Quinolones

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; AZLOCILLIN; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEFMENOXIME; CEFOXITIN; CEFPODOXIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; ENOXACIN; FUSIDIC ACID; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; LOMEFLOXACIN; MACROLIDE; METRONIDAZOLE; OFLOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN; QUINOLONE DERIVATIVE; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CONFERENCE PAPER; DRUG TOLERANCE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; POSTANTIBIOTIC EFFECT;

4-QUINOLONES; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CARBAPENEMS; CEPHALOSPORINS; DRUG ADMINISTRATION SCHEDULE; GLYCOPEPTIDES; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLINS;

EID: 0030848280     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (90)

1. Garraffo R. Optimal adaptive control of pharmacodynamic effects with aminoglycoside antibiotics: a required approach for the future. Int J Biomed Comput 1994; 36: 43-57.
2. MacGowan AP. Concentration controlled and concentration defined clinical trials: do they offer any advantages for antimicrobial chemotherapy? J Antimicrob Chemother 1996; 37: 1-6.
3. Shah PM., Ghabremani M, Corres F-J et al. Bactericidal activity of antimicrobials in the dynamic kill-curve model. J Drug Dev 1988; 1 (Suppl 3): 35-47.
4. Sous H, Hirsch I. Bactericidal activity of phenoxymethyl-penicillin in an in vitro model simulating tissue kinetics. J Antimicrob Chemother 1995; 15 (Suppl A); 233-239.
5. Hyatt JM, Nix DE, Stratton CW, Schentag JJ. In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam and ciprofloxacin alone and in combination against Staphylocaccus aureus, Klebsiella pneumoniae, Enterobacter cloacae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995; 39: 1711-1716.
6. Odenholt-Tornquist I. Pharmacodynamics of beta-lactam antibiotics. Scand J Infect Dis 1989, Suppl 58.
7. Craig WA, Ebert SC. Continuous infusion of β-lactam antibiotics. Antimicrob Agents Chemother 1992; 36: 2577-2583.
8. Bundtzen RW, Gerber AU, Cohn DL, Craig WA. Post antibiotic suppression of bacterial growth. Rev Infect Dis 1981; 3: 28-37.
9. Sande MA, Korzeniowski OM, Allegro GM, Brennan RO, Zak O, Scheld WM. Intermittent and continuous therapy of experimental meningitis due to Streptococcus pneumoniae in rabbits: preliminary observations on the post antibiotic effect in vivo. Rev Infect Dis 1981; 3: 98-109.
10. McDonald PJ, Wetherall BL, Pruul H. Post antibiotic leukocyte enhancement: increased susceptibility of bacteria pre treated with antibiotics to activity of leukocytes. Rev Infect Dis 1981; 3: 38-44.
11. Odenholt I, Holm SE, Cars O. Effects of supra and sub MIC benzyl penicillin concentrations on Group A β-haemolytic streptococci during the post antibiotic phase in vivo. J Antimicrob Chemother 1990; 26: 193-201.
12. Oshida T, Onta T, Nakanishi N, Matsushita T, Yamaguchi T. Activity of sub-minimal inhibitory concentrations of aspoxicillin in prolonging the post antibiotic effect against Staphylococcus aureus. J Antimicrob Chemother 1990; 26: 29-38.
13. Jones EM, MacGowan AP. The antimicrobial chemotherapy of human infection due to Listeria monocytogenes. Eur J Clin Microbiol Infect Dis 1995; 14: 165-175.
14. van Asselt GJ, Mouton RP, van Boven CPA. Penicillin tolerance and treatment failure in Group A streptococcal pharyngotonsillitis. Eur J Clin Microbiol Infect Dis 1996; 15: 107-115.
15. Tuomanen E, Durack DT, Tomasz A. Antibiotic tolerance among clinical isolates of bacteria. Antimicrob Agents Chemother 1986; 30 521-527.
16. James PA. Comparison of four methods for determination of MIC and MBC of penicillin for viridans streptococci and implications for penicillin tolerance. J Antimicrob Chemother 1990; 25: 209-216.
17. White CA, Toothaker RD. Influence of ampicillin half-life on in vitro bacterial effect. J Antimicrob Chemother 1985; 15 (Suppl A): 257-260.
18. Thaurin C, Eliopoulos GM, Willey S, Wennersten C, Moellering RC. Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats. Antimicrob Agents Chemother 1987; 31: 139-143.
19. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831-847.
20. Weinstein MP, Stratton CW, Ackley A, et al. Multicenter collaborative evaluation of a standardised serum bactericidal test as a prognostic indicator in infective endocarditis. Am J Med 1985; 78: 262-269.
21. Weinstein MP, Stratton CW, Hawley HB, Ackley A, Reller LB. Multicenter collaborative evaluation of a standardised serum bactericidal test as a predictor of therapeutic efficacy in acute and chronic oesteomyelitis. Am J Med 1987; 83: 218-222.
22. Jones BL, Ludlam HA, Brown DFJ. High dose ampicillin for the treatment of high level aminoglycoside resistant enterococcal endocarditis. J Antimicrob Chemother 1994; 33: 891-892.
23. Körner RJ, Nicol A, Reeves DS, MacGowan AP, Hows J. Ciprofloxacin resistant Serratia marcescens endocarditis as a complication of non-Hodgkins lymphoma. J Infect 1994; 29: 73-76.
24. Vogelman BS, Craig WA. Post antibiotic effects. J Antimicrob Chemother 1985; 15 (Suppl A): 37-46.
25. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis 1991; Suppl 74: 63-70.
26. Leggett JE, Fantin B, Ebert S, et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159: 281-292.
27. Roosendaal R, Bakker-Woudenberg AJ, van den Berghe-van Raffe M, Vink Van den Berg JC, Michel MF. Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicaemia in leukopenic rats. Eur J Clin Microbiol Infect Dis 1989; 8: 878-887.
28. Mouton JW, den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994; 38: 931-936.
29. Cappelletty DM, Kang SL, Palmer SM, Rybak MJ. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily dose amikacin against Pseudomonas aeruginosa in an in vitro infection model. Antimicrob Agents Chemother 1995; 33: 1797-1801.
30. Garrison MW, Malone CL, Eiland JE. Activity of once daily cefpodoxime regimens against Haemophilus influenzae and Streptococcus pneumoniae with an in vitro pharmacodynamic chamber model. Antimicrob Agents Chemother 1996; 40: 1545-1547.
31. Mouton JW, Horrevorts AM, Mulder PGH, Prens EP, Michel MF. Pharmacokinetics of ceftaxidime in scrum and suction blister fluid during continuous and intermittent infusions in health volunteers. Antimicrob Agents Chemother 1990; 34: 2307-2311.
32. Daenen S, Erjavec Z, Uges DRA, De Vries-Hospers MG, De Jonge P, Halie MR. Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukaemia. Eur J Clin Microbiol Infect Dis 1995; 14: 188-192.
33. Benko AS, Cappelletty DM, Kruse JA, Rybak MJ. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected Gram-negative infection. Antimicrob Agents Chemother 1996; 40: 691-695.
34. Nicolau DP, Nightingale CH, Benevicius MA, Feu Q, Quintiliani R. Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injection. Antimicrob Agent Chcmothcr 1996; 40: 61-64.
35. Daenen S, de Vries-Hospers H. Cure of Pseudomonas aeruginosa infection in neutropenic patients by continuous infusion of ceftazidime. Lancet 1988; i:937.
36. David TJ, Devlin J. Continuous infusion of ceftazidime in cystic fibrosis. Lancet 1989; i: 1454.
37. Kuzemko J, Crawford C. Continuous infusion of ceftazidime in cystic fibrosis. Lancet 1989; ii: 385.
38. Bodey GP, Ketchel SJ, Rodriguez V. A randomised study of carbenicillin plus cefamandole or tobramycin in treatment of febrile episodes in cancer patients. Am J Med 1979; 67: 608-616.
39. Schentag JJ. Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationship between serum concentrations, MIC values and bacterial eradication in patients with Gram-negative pneumonia. Scand J Infect Dis 1991: Suppl 74: 218-234.
40. Goss T, Forrest A, Nix DE, Ballow CH, Birmingham MC, Cumbo TJ, Schentag JJ. Mathematical examination of dual individualisation principles (II): the rate of bactericidal eradication at the same area under the inhibitory curve is more rapid tor ciprofloxacin than for cefmenoxime. Ann Pharmacother 1994; 28: 863-868.
41. McGrath BJ, Marchbanks CR, Gilbert D, Dudley MN. In vitro post antibiotic effect following repeated exposure to imipenem, temafloxacin and tobramycin. Antimicrob Agents Chemother 1993; 37: 1723-1725.
42. Fuentes F, Martin MM, Izquierdo J, Gomez Lus ML, Prieto J. In vivo and in vitro study of several pharmacodynamic eftects of meropenem. Scand J Infect Dis 1995; 27: 469-474.
43. Hanberger H, Nilsson LL, Nilsson M, Maller R. Post antibiotic effect of beta-lactams antibiotics on Gram-negative bcteria in relation to morphology, initial killing and MIC. Eur J Clin Microbiol Infect Dis 1991; 10, 11: 927-934.
44. Odenholt-Tornquist I. Studies the post antibiotic effect and the post antibiotic sub MIC effect of meropenem. J Antimicrob Chemother 1993; 31: 881-892.
45. Mackenzie FM, Gould IM, Chapman DG, Jason D. Post antibiotic effect of meropenem on members of the family Enterobacteriaceae determined by live methods. Antimicrob Agents Chemother 1994, 38, 11: 2583-2589.
46. Ferrara A, Grassi G, Grassi F, Piccioni PD, Gialdroni Grassi G. Bactericidal of meropenem and interactions with other antibiotics. J Antimicrob Chemother 1989; 24: (Suppl A) 239-250.
47. White R, Friedrich L, Burgess D, Warburton D, Bosso J. Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40: 904-908.
48. Bowker KE, Holt HA, Reeves DS, MacGowan AP. Bactericidal activity, post antibiotic effect and modified controlled effective regrowth time of meropenem at high concentrations. J Antimicrob Chemother 1996; 38: 1055-1059.
49. Maggiola F, Taras A, Frontespezi S, Boltari F, Legnani MC, Suter F. Bactericidal activity of two different dosage regimes of imipenem in an in vitro dynamic model. J Antimicrob Chemother 1993; 32: 295-300.
50. Fluckiger V, Segessenman C, Gerber AV. Integration of pharmacoeconomics and pharmacodynamics of imipenem in a human adapted mouse model. Antimicrob Agents Chemothcr 1991; 35: 1905-1910.
51. Edwards JR. Meropenem: a microbiological overview. J Antimicrob Chemother 1995; 36: Suppl A, 1-17.
52. Nilsson LE, Nilsson M, Jendle J. Sub populations of variants resistant to imipenem in Pseudomonas aeruginosa. J Antimicrob Chemother 1998; 22: 643-649.
53. Walker R, Andes D, Cinklin R, Ebert SC, Craig W. Pharmacodynamic activities in an animal infection model. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Washington DC: 1994, Abstr A91.
54. Romanelli G, Cravarezza P, and the Italian Intramuscular Meropenem Study Group. Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. J Antimicrob Chemother 1995; Suppl A: 109-119.
55. MacGowan AP, Bowker KE, Lovering AM, Brown IM, Darley ESR, Reeves DS, Harvey JE. Once-a-day carbapenem therapy. J Antimicrob Chemother 1996; 38: 327-328.
56. Kang SL, Rybank MJ, McGrath BJ, Kaatz GW, Seo SM. Pharmacodynamics of levofloxacin, ofloxacin and ciprofloxacin alone and in combination with rifampicin against methicillin resistant Staphylococcus aureus in an in vitro infection model. Antimicrob Agents Chemother 1994; 38: 2702-2709.
57. Mackenzie FM, Gould IM. The post antibiotic effect. J Antimicrob Chemother 1993; 32: 519-537.
58. Wiedemann B, Kratz B. The post antibiotic effect of ciprofloxacin. In: Ciprofloxacin iv defining its role in serious infections. Ed: Carrard C. Springer-Verlag, London 1994: 11-19.
59. Bauernfeind A, Kljucar S. Dose-finding investigations of intravenous ciprofloxacin in a pharmacodynamic model. In: Ciprofloxacin iv defining its role in serious infections. Ed: Garrard C. Springer-Verlag, London 1994; 39-48.
60. Reeves DS. Advantages and disadvantages of an in vitro model with two compartments connected by a dialysiser results of experiments with ciprofloxacin. J Antimicrob Chemother 1985; 15, Suppl A: 159-167.
61. Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31: 1054-1060.
62. Drusano GL, Johnson DE, Rosen M, Standford HC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993; 37: 483-490.
63. Sullivan MC, Cooper BW, Nightingale CM, Quintiliani R, Lawlor MT. Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model. Antimicrob Agents Chemother 1993; 37: 234-239.
64. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-1081.
65. 2+ and albumin on these drugs. Antimicrob Agents Chemother 1991; 35: 1710-1716.
66. Bailey EM, Rybak MJ, Kaatz GW. Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrob Agents Chemother 1991; 35: 1089-1092.
67. Ackerman BH, Vannier AM, Eudy EB. Analysis of vancomycin time kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response. Antimicrob Agents Chemother 1992; 36: 1766-1769.
68. Contrepois A, Joly V, Abel L, Pangon B, Vallois J-M, Carbon C. The pharmacokinetics and extravascular diffusion of teicoplanin in rabbits and comparative efficacy with vancomycin in an experimental endocarditis mode. J Antimicrob Chemother 1988; 21: 621-631.
69. Chambers HF, Kennedy S. Effects of dosage, peak and trough concentrations in serum, protein binding and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob Agents Chemother 1990; 34: 510-514.
70. Wilson APR, Gruneberg RN, Neu H. A critical review of the dosage of teicoplanin in Europe and the USA. Int J Antimicrob Agents 1994; 4 (Suppl 4): S1-S30.
71. Leport C, Perronne C, Massip P, et al. Evaluation of teicoplanin for treatment of endocarditis caused by Grampositive cocci in 20 patients. Antimicrob Agents Chemother 1989; 33: 871-876.
72. MacGowan AP, White LO, Harding I, Reeves DS. A retrospective review of serum teicoplanin concentration in clinical trials and their relationship to clinical outcome. J Infect Chemother (in press).
73. Jackson GG, Daikos GL, Lolans VT. First-exposure effect of netilmicin on bacterial susceptibility as a basis for modifying the dosage regimen of aminoglycoside antibiotics. J Drug Dev 1988; 1 (Suppl 3): 49-54.
74. Daikos GL, Jackson GG, Lolans VT, Livermore DM. Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis 1990; 162: 414-420.
75. Blaser J. Efficacy of once- and thrice-daily dosing of aminoglycosides in in vitro models of infection. J Antimicrob Chemother 1991; 27 (Suppl C); 21-28.
76. Begg EJ, Peddie BA, Chambers ST, Boswell DR. Comparison of gentamicin dosing regimens using an in vitro model. J Antimicrob Chemother 1992; 29: 427-433.
77. Powell SH, Thompson WL, Luthe MA, et al. Once-daily vs continuous aminoglycoside dosing, efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin and tobramycin. J Infect Dis 1983; 147: 918-932.
78. Craig WA, Redington J, Ebert SC. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 1991; 27 (Suppl C): 29-40.
79. Preston SL, Briceland LL. Single daily dosing of aminoglycosides. Pharmacotherapy 1995; 15: 297-316.
80. Blaser J, Konig C. Once daily dosing of aminoglycosides. Eur J Clin Microbiol Infect Dis 1995; 14: 1029-1058.
81. Barza M, Ionnidis JPA, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. Br Med J 1996; 312: 338-345.
82. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996; 124: 717-725.
83. Munckhot WJ, Grayson ML, Turnidge JD. A metaanalysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996; 37: 645-663.
84. Ferriols-Lisart R, Alos-Alminana M. Effectiveness and safety of once-daily aminoglycosides: a meta analysis. Am J Health-Syst Pharm 1996; 53: 1141-1150.
85. Prins JM, Buller HR. Meta-analysis: the final answer, or even more confusion. Lancet 1996; 348: 199.
86. Nicolau DP, Freeman CD, Belliveau PB, Nightingale CH, Ross JW, Quintiliani R. Experience with a one-daily aminoglycoside program administered to 2184 adult patients. Antimicrob Agents Chemother 1995; 39: 650-655.
87. MacGowan AP, Reeves DS. Serum monitoring of once-daily aminoglycoside dosing. J Antimicrob Chemother 1994; 33: 349-350.
88. Ettlinger JJ, Bedford KA, Lovering AM, Reeves DS, Speidel BD, MacGowan AP. Pharmacokinetics of once-a-day netilmicin (6 mg/kg) in neonates. J Antimicrob Chemother 1996; 38: 499-505.
89. Kang SL, Rybak MJ. Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin model. Antimicrob Agents Chemother 1995; 39: 1505-1511.
90. Bauernfeind A, Jungwirth R, Ebertein E. Comparative pharmacodynamics of clarithromycin and azithromycin against respiratory pathogens. Infection 1995; 23: 66-71.